Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 3, Pages e92146
Publisher
Public Library of Science (PLoS)
Online
2014-03-21
DOI
10.1371/journal.pone.0092146
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
- (2015) Takayuki Yoshida et al. Oncotarget
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- Inconsistency in large pharmacogenomic studies
- (2013) Benjamin Haibe-Kains et al. NATURE
- Metrics other than potency reveal systematic variation in responses to cancer drugs
- (2013) Mohammad Fallahi-Sichani et al. Nature Chemical Biology
- 2012 FDA drug approvals
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Implementing personalized cancer genomics in clinical trials
- (2013) Richard Simon et al. NATURE REVIEWS DRUG DISCOVERY
- Comparability of Mixed IC50 Data – A Statistical Analysis
- (2013) Tuomo Kalliokoski et al. PLoS One
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
- (2013) Alastair J. King et al. PLoS One
- A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets
- (2012) Joost CM Uitdehaag et al. BRITISH JOURNAL OF PHARMACOLOGY
- System-based drug discovery within the human kinome
- (2012) Paul Bamborough Expert Opinion on Drug Discovery
- Activity-based kinase profiling of approved tyrosine kinase inhibitors
- (2012) Daisuke Kitagawa et al. GENES TO CELLS
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Objective assessment of cancer genes for drug discovery
- (2012) Mishal N. Patel et al. NATURE REVIEWS DRUG DISCOVERY
- A theoretical entropy score as a single value to express inhibitor selectivity
- (2011) Joost CM Uitdehaag et al. BMC BIOINFORMATICS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Navigating the kinome
- (2011) James T Metz et al. Nature Chemical Biology
- c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways and drive metastatic progression
- (2011) S S Ganguly et al. ONCOGENE
- The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors
- (2010) Björn Koos et al. CANCER
- Molecular Target Class Is Predictive of In vitro Response Profile
- (2010) Joel Greshock et al. CANCER RESEARCH
- Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells
- (2010) Shujie Zhao et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity
- (2010) J. Colicelli Science Signaling
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- De novo synthesis of β-catenin via H-Ras and MEK regulates airway smooth muscle growth
- (2009) Reinoud Gosens et al. FASEB JOURNAL
- Selectively Nonselective Kinase Inhibition: Striking the Right Balance
- (2009) Richard Morphy JOURNAL OF MEDICINAL CHEMISTRY
- EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor
- (2009) J-J Li et al. ONCOGENE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started